Ovarian carcinoma (high-grade serous predominant) · line 2 · Weekly Paclitaxel + Bevacizumab (platinum-resistant recurrent ovarian, AURELIA)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 2 |
|---|---|
| Track | standard |
| Linked regimen | REG-WEEKLY-PAC-BEV-OVARIAN |
| ID | IND-OVARIAN-2L-PLAT-RES-WEEKLY-PAC-BEV |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | DIS-OVARIAN |
| Sources | SRC-AURELIA-PUJADE-LAURAINE-2014 SRC-ESMO-OVARIAN-2024 SRC-NCCN-OVARIAN-2025 |
Notes
ESCAT IB. Preferred AURELIA backbone when no residual neuropathy. Full NSZU coverage of both components — primary UA platinum-resistant 2L recommendation.
Used By
Algorithms
ALGO-OVARIAN-2L- ALGO-OVARIAN-2L